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Vancomycin
Heteroresistance
in Methicillin-
resistant
Staphylococcus
aureus, Taiwan
To the Editor: In 1997, Hiramatsu
and colleagues reported the first clini-
cal isolate of methicillin-resistant
Staphylococcus aureus (MRSA)
showing reduced susceptibility to
vancomycin (1). Soon thereafter, van-
comycin-intermediate  S. aureus
(VISA) or heteroresistant VISA was
reported to have disseminated in
Japanese hospitals (2). In Taiwan, a
survey of >5,000 clinical isolates of S.
aureus at one tertiary medical center
from 1999 to 2001 showed negative
results for VISA or vancomycin-
resistant S. aureus (VRSA) (3,4). We
report the first two isolations of het-
eroresistant VISA in Taiwan.
In June, 2000, an 89-year-old man
(patient A) with a history of cere-
brovascular accident underwent ileal
resection for ischemic bowel disease,
and primary MRSAbacteremia devel-
oped during the hospitalization.
Vancomycin was given for 14 days,
and his fever rapidly abated. In
October 2000, a Port-A-Cath (Smiths
Industries Medical Systems, Deltec,
Inc., St. Paul,MN) was inserted in the
left subclavian vein. On June 14,
2001, he had another blood isolate of
MRSA during an episode of
Enterococcus faecalis bacteremia.
Fever resolved after 4 days of intra-
venous vancomycin treatment (1 g
every 12 h), and vancomycin treat-
ment was continued for 21 days.
Subsequent culture of blood drawn
from the Port-A-Cath and peripheral
veins on June 29 and July 6, 2001, did
not yield any organism. MRSA bac-
teremia relapsed in November 2001,
and the patient received intravenous
teicoplanin treatment (400 mg every 2
days) for 3 weeks, and fever resolved
rapidly. Transthoracic echocardio-
grapic tests showed no vegetation on
the cardiac valves. The patient was
hospitalized again in March 2002
because of relapsing MRSA bac-
teremia. The Port-A-Cath was
removed, and culture of fluid from
the indwelling pocket yielded MRSA.
Fever and MRSA bacteremia persist-
ed, with 17 sets of positive blood cul-
ture from March to May 2002, even
under an adequate dose of intra-
venous vancomycin (serum trough
level of vancomycin = 9–24 µg/mL
and serum peak level = 18–30
µg/mL) and rifampin (600 mg/day).
An infected thrombus over the sub-
clavian vein was detected by venous
duplex and thought to be an unre-
solved focus. Linezolid (600 mg
every 12 h) was given for 10 days
(April 30–May 9, 2002) but discon-
tinued because of progressive throm-
bocytopenia. Vancomycin and rifam-
pin were resumed on May 10, and
positive blood culture with MRSA
was noted on May 14. Oliguric renal
failure developed in the patient on
May 21 followed by shock, and he
died on May 23. 
A72-year-old man (patient B) with
coronary artery disease and chronic
renal insufficiency underwent coro-
nary artery bypass grafting and aortic
grafting for abdominal aortic
aneurysm in December 1999. The
postoperative course was complicated
with second-degree atrioventricular
block and progressive renal failure.
He was implanted with a permanent
pacemaker and started long-term
hemodialysis in March 2000. In April
2000, catheter (double lumen for
hemodialysis)-related MRSA bac-
teremia developed in the patient.
Vancomycin (1 g/week) was adminis-
tered and the catheter was changed,
but 17 successive episodes of MRSA
bacteremia recurred from May to July
2000, despite an adequate serum level
of vancomycin (trough level = 13–21
µg/mL and peak level = 24–38
µg/mL). Transesophageal echocardio-
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graphy showed vegetation on the tri-
cuspid valve. Vancomycin was
changed to teicoplanin (400 mg every
3 days) because of vancomycin-asso-
ciated skin rashes and eosinophilia,
and the treatment was continued for 1
month. No MRSA infection was
found in the subsequent 6 months. In
January 2001, a subcutaneous abscess
and osteomyelitis developed over the
right humerus after the patient was
injured in a fall, and bacteremia sub-
sequently developed. Local debride-
ment was performed, and glycopep-
tides were given for 6 weeks (van-
comycin for 12 days and teicoplanin
for 30 days). From March to April
2001, he had repeated episodes of
MRSA bacteremia associated with
pus discharge from the pacemaker
insertion site. The pacemaker was
removed, and high-dose teicoplanin
(600 mg every 3 days) was given for
4 months, during which time MRSA
bacteremia did not recur.
MICs of vancomycin were deter-
mined for the 21 isolates of MRSA
from the two patients (Table) by the
broth microdilution and agar dilution
method using brain-heart infusion
(BHI) agar or broth and Mueller-
Hinton agar (MHA) or broth (BBL
Microbiology Systems, Cockeysville,
MD), according to the recommenda-
tions by the National Committee for
Clinical Laboratory Standards (5).
Vancomycin MICs were also deter-
mined by the Etest (AB Biodisk,
Solna, Sweden) by swabbing 0.5
McFarland Standard on a BHI agar
plate, and the results were read after
incubation for 24 h. Mu3 and Mu50
were used as control strains. MICs of
the following antimicrobial agents
were also determined by using the
agar dilution method: oxacillin (MHA
plus 2% NaCl) and teicoplanin,
fusidic acid, and linezolid (MHA). 
All 21 isolates were highly resist-
ant to oxacillin (MICs > 128 µg/mL)
but susceptible to linezolid (MICs =
1–2 µg/mL) and fusidic acid (MICs =
0.06–0.25  µg/mL). Isolates with
reduced susceptibility to vancomycin
(MICs  > 4  µg/mL, determined by
more than one method) included A6
and A7 from patient A and B7 from
patient B. Two isolates (B6 and B7)
had Etest vancomycin MICs of
8 µg/mL, and one of them also had an
MIC of 5 µg/mL by the agar dilution
method (Table). 
Analysis of the vancomycin-resist-
ant subpopulation of two MRSA iso-
lates (A7 and B7) from the two
patients, one isolate (isolate C, Etest
vancomycin MIC = 4 µg/mL) of
MRSA recovered from a patient with
bacteremia in 2000, and Mu3 was per-
formed according to the description
by Hiramatsu et al. (1,2). Hetero-
resistant VISA refers to isolates with
vancomycin MICs for one or more
subpopulations above the susceptible
range (i.e., > 4 µg/mL) (1,2). Isolates
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Table. Characteristics of 21 methicillin-resistant Staphylococcus aureus isolates recovered from two patients with recurrent bacteremia
a
Vancomycin MIC (Pg/mL) 
Teicoplanin MIC 
(Pg/mL) 
Etest  Broth microdilution  Agar dilution  Agar dilution 
Designation of isolate 
Date of isolation 
(mo/day/year)  BHI BHI MHB  BHI  MHA  MHA 
Patient A (89-y-old man)               
A1 6/30/2000  3  2  1  2  2  2 
A2 6/14/2001  4  3  1  2  2  2 
A3 11/19/2001  4  4  2  2  2  2 
A4 3/5/2002  4  3  1  2  2  4 
A5 3/22/2002  4  3  2  3  2  4 
A6 4/3/2002  6  5  4  4  2  4 
A7 4/14/2002  6  5  4  4  3  4 
A8 4/29/2002  5  4  2  4  3  8 
A9 4/29/2002  6  3  2  4  3  4 
A10 5/7/2002  6  4  2  4  2  4 
Patient B (72-y-old man)               
B1 4/26/2000  3  2  1  2  1  2 
B2 5/6/2000  4  2  1  2  2  8 
B3 5/18/2000  6  4  2  4  3  8 
B4 5/29/2000  5  4  1  4  2  8 
B5 6/15/2000  6  3  2  4  3  8 
B6 6/24/2000  8  4  2  4  3  8 
B7 7/19/2000  8  4  3  5  3  8 
B8 1/9/2001  4  1  1  2  1  1 
B9 1/26/2001  4  2  1  2  1  1 
B10 3/21/2001  3  2  1  2  1  1 
B11 4/6/2001  4  2  1  2  1  1 
Mu3   3  3  2  3  2  – 
Mu50   10  8  5  8  4      – 
aBHI, brain heart infusion; MHB, Mueller-Hinton broth; MHA, Mueller-Hinton agar. LETTERS
of A7 and B7, like the
Mu3 strain, contained
resistant subpopulations
that grew in >4  µg/mL
vancomycin and were
thus considered as het-
eroresistant VISA strains
(Figure). 
Pulsed-field gel elec-
trophoresis analysis after
digestion of chromoso-
mal DNA with XbaI
showed that 10 isolates
from patient A belonged
to pulsotype a and those
from patient B belonged
to pulsotype b (Table). Heteroresistant
VISA isolates were genetically indis-
tinguishable from vancomycin-sus-
ceptible isolates.
This report is the first of heterore-
sistant VISA causing clinical infec-
tion in Taiwan, although the clinical
importance of heteroresistant VRSA
infection is unclear. While a previous
report described no treatment failure
of patients infected with heteroresis-
tant VRSA strains (6), another study
found higher death rate in patients
infected with vancomycin-heterore-
sistant staphylococci (7). A recent
case-control study of varying degrees
of vancomycin susceptibility in
MRSA bacteremia did not conclude
whether a clinical difference was
noted between bacteremia attributable
to heteroresistant VISA and homoge-
neously susceptible strains (8). This
report describes recurrent bacteremia
caused by a single clone of MRSA
that possessed subpopulations with
different glycopeptide susceptibilities
during different periods of treatment.
These heteroresistant VISA strains
were associated with prolonged gly-
copeptide use and glycopeptide treat-
ment failure. Biofilm formation in the
implanted intravascular devices may
explain the relapsing nature in these
two patients (9), and these heterore-
sistant VRSA strains might contribute
to lack of bacteriologic eradication in
infected valves and intravascular
thrombi (10). Linezolid, having good
in vitro activity against MRSA with
reduced susceptibility to vancomycin,
still failed to eradicate the organism
within the infected thrombus in
patient A.
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Figure. Population analysis of Mu3, two methicillin
Staphylococcus aureus (MRSA) isolates (isolates A7 and
B7) with heteroresistance to vancomycin, and one van-
comycin-susceptible MRSA (isolate C).
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